Skip to main content
Premium Trial:

Request an Annual Quote

PacBio, VisiGen, Helicos Offer Progress Updates


This year started off with a bang for the next-gen sequencing community. At two February conferences — Advances in Genome Biology and Technology in Marco Island, Fla., and the Association of Biomolecular Resource Facilities annual meeting in Salt Lake City — representatives from a number of the next line of next-gen vendors gave status reports on their platforms.

It can safely be said that the most anticipated came from Pacific Biosciences, which emerged from stealth mode with results from its prototype instrument. Known as SMRT sequencing (that's "single molecule, real-time"), the technology is currently running at 10 bases per second, and tests with circularized templates have routinely generated reads of 1,500 bases or more. The company has a staff of 100 and expects to double in size this year, says CEO Hugh Martin — he'll also be looking to raise about $80 million in funding to cover commercialization costs. Martin says PacBio expects to be selling instruments to early adopters in 2010, and that its price is targeted to be in the same range as ABI's SOLiD or Illumina's next-gen sequencer. CTO Steve Turner says the instrument has successfully worked with linear and circular, as well as single- and double-stranded, DNA.

Susan Hardin presented VisiGen's sequencer at ABRF. Like PacBio's technology, VisiGen monitors a polymerase in real time as it incorporates bases to a DNA strand to read the sequence. The platform is still in early stages, but she said her initial target was to generate 1 megabase of sequence per second per instrument, and that the company would be offering a sequencing service by the end of 2009. She also said that the company was awarded its first patent.

Helicos, meanwhile, announced its first instrument order — to genomic services provider Expression Analysis in Durham, NC — and also presented results of a canine BAC that the company had sequenced. The single-molecule platform uses a melt-and-resequence strategy to cover each base twice, said Bill Efcavitch, senior vice president of product R&D. "One of the advantages of single-molecule sequencing is that the error rate stays flat," he added.

Also at AGBT, a team from Danaher Motion ushered attendees in to introduce them to the Polonator, the open-platform sequencer commercialized from George Church's lab with a price tag of $150,000.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.